Roth/MKM upgrades Tilray stock on international growth, cost savings

Roth/MKM upgraded Tilray Brands to Buy with a $10 price target vs the current $6.14 stock price (≈63% upside) and InvestingPro flags a Fair Value of $8.41. The upgrade cites stabilizing Canadian operations, improving international performance, advantages from CC Pharma and BrewDog cost savings, slowing share issuance and lower cost of capital; the $10 PT implies ~12x EV/EBITDA vs the current ~8x. Tilray also reported strong Q3 FY2026 results (period ended Feb 28) with meaningful revenue and net income improvement, and analysts forecast the company will be profitable this year.

Analysis

Tilray’s operational improvement should shift the competitive map from a pure market-share scramble to an execution premium — investors who value steady cash conversion and integration of non-cannabis businesses will benefit while capital-starved, single-market LPs face consolidation pressure. The most important second-order effect is on distribution economics: stronger beverage and pharma channels compress the effective customer-acquisition cost curve and raise switching costs for retail partners, making scale and diversified routes-to-market a durable moat if maintained for 6–18 months.

Key risks hinge on three timing windows. Over the next 3 months, macro funding liquidity and any re-acceleration of share issuance can quickly reprice multiples; over 6–12 months, margin sustainability depends on SG&A and BrewDog integration deliverables and on pharma revenue cadence; over 12–36 months, regulatory shifts in the U.S. or EU excise changes are binary events that can re-rate the whole sector. Currency and energy inputs for cultivation are wildcards that can erode the near-term margin uplift even if top-line diversification holds.

The market’s constructive reaction understates two fragilities: (1) execution risk in turning recent one-off cost saves into permanent lower operating leverage, and (2) the relative valuation sensitivity to renewed M&A activity — a deal would likely be additive to equity but dilutive if paid with stock. For traders, the most actionable window is the next 6–12 months where operational evidence (quarterly gross margin and free-cash-flow trends) will resolve the story; allocate size to be able to add or trim as those metrics print against consensus.

Key Decisions for Investors

• Long TLRY via a 9–12 month call spread (buy longer-dated calls, sell higher strikes) sized at 2–4% portfolio — objective: capture asymmetric upside from continued margin improvement while capping premium lost if execution stalls; ideal payoff if FCF turns sustainably positive within 12 months (target 2–3x return vs premium).
• Pair trade: long TLRY / short CGC (equal-dollar) for 6–12 months to express selection among Canadian LPs — hedges sector/systemic risk while isolating execution premium; trim if both names rally with sector-wide multiple expansion.
• Event hedge: buy 3–6 month TLRY puts (small position) ahead of next two quarterly prints to protect against upside evaporating from renewed share issuance or missed integration milestones — cost should be <1% portfolio to limit drag but cap tail risk.
• Monitor M&A trigger: if a credible bidder emerges or regulatory clarity improves, convert option exposure to long equity within 30 days and target partial profit-taking at multi-quarter margin inflection points; conversely, if cash burn reappears, exit quickly to preserve capital.